TimesSquare Capital Management LLC Buys 209,009 Shares of Vericel Co. (NASDAQ:VCEL)

TimesSquare Capital Management LLC lifted its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 54.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 590,145 shares of the biotechnology company's stock after purchasing an additional 209,009 shares during the quarter. TimesSquare Capital Management LLC owned 1.20% of Vericel worth $24,934,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Nisa Investment Advisors LLC increased its holdings in shares of Vericel by 9.7% in the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company's stock valued at $114,000 after purchasing an additional 220 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company's stock worth $77,000 after acquiring an additional 322 shares during the last quarter. Swiss National Bank lifted its stake in shares of Vericel by 0.4% during the first quarter. Swiss National Bank now owns 89,500 shares of the biotechnology company's stock valued at $4,656,000 after acquiring an additional 400 shares during the period. PFG Investments LLC boosted its holdings in Vericel by 6.2% in the second quarter. PFG Investments LLC now owns 6,850 shares of the biotechnology company's stock valued at $314,000 after acquiring an additional 400 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 405 shares during the last quarter.

Insider Activity at Vericel

In related news, Director Steven C. Gilman sold 5,833 shares of the firm's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total value of $241,252.88. Following the completion of the transaction, the director now directly owns 11,000 shares of the company's stock, valued at approximately $454,960. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Dominick Colangelo sold 17,500 shares of the firm's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the sale, the chief executive officer now owns 220,937 shares in the company, valued at approximately $9,142,373.06. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Steven C. Gilman sold 5,833 shares of the company's stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total value of $241,252.88. Following the completion of the transaction, the director now directly owns 11,000 shares in the company, valued at $454,960. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,166 shares of company stock valued at $1,200,764. 5.20% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group assumed coverage on shares of Vericel in a research note on Friday, August 9th. They set a "buy" rating and a $57.00 price target for the company. BTIG Research decreased their price objective on Vericel from $56.00 to $55.00 and set a "buy" rating for the company in a research note on Monday, July 15th. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Vericel in a research note on Friday. TD Cowen upped their price target on Vericel from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Tuesday, August 27th. Finally, Canaccord Genuity Group initiated coverage on shares of Vericel in a report on Friday, August 9th. They set a "buy" rating and a $57.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.71.

Vericel Stock Up 5.1 %

VCEL traded up $2.78 during trading on Monday, hitting $56.78. The company had a trading volume of 596,221 shares, compared to its average volume of 430,598. The firm's 50-day moving average price is $44.27 and its 200 day moving average price is $46.41. The company has a market capitalization of $2.78 billion, a PE ratio of 946.49 and a beta of 1.66. Vericel Co. has a one year low of $32.31 and a one year high of $57.35.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The business had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. Sell-side analysts forecast that Vericel Co. will post 0.13 earnings per share for the current year.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.